Cancer treatment and research communicationsHumansCarboplatinEtoposideLung NeoplasmsAntineoplastic Combined Chemotherapy Protocols
Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study).
Hidenobu Ishii, Koichi Azuma, Fumiaki Kiyomi, Kohei Yoshimine, Kazuki Uchida, Kazunori Tobino, Tadaaki Yamada, Tsutomu Iwasa, Hiroaki Kanemura, Toshiyuki Sumi, Eiji Iwama, Masataka Mori, Masaru Takenaka, Yuki Takeyasu, Takayasu Kurata
Published: 202510.1016/j.ctarc.2025.101008
Abstract
INTRODUCTION: Large cell neuroendocrine carcinoma (LCNEC) of the lung is a rare histologic type and is placed in the neuroendocrine tumor category along with small cell lung cancer (SCLC) at the latest histologic classification. Combination therapy w…
Preview only. Read the full abstract at the source